New hope for head and neck cancer: smart drug targets tumors, boosts immune system
NCT ID NCT07408063
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests a new drug, GSK5764227, that delivers chemotherapy directly to cancer cells, either alone or with an immunotherapy called dostarlimab. The study enrolls 30 people with recurrent or metastatic head and neck cancer. Researchers will analyze tumor samples and blood tests to find markers that predict response or resistance, aiming to personalize future treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- GSK5764227 (antibody drug conjugate) and dostarlimab (immunotherapy)
- What this could lead to
- If successful, this could identify which patients benefit most from this drug combination, potentially leading to more personalized treatment for head and neck cancer.
- What could go wrong
- This is a small, early-phase trial (30 people) focused on finding biomarkers, not proving a cure. The drugs may not work for many patients, and side effects from the chemotherapy-like payload are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT/METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Princess Margaret Cancer Centre
RECRUITINGToronto, Ontario, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug cocktail aims to tackle recurrent head and neck cancer
- New drug combo targets Hard-to-Treat head and neck cancers
- Promising drug cocktail targets Hard-to-Treat head and neck cancer
- New drug combo targets Hard-to-Treat head and neck cancer
- New hope for head and neck cancer: drug combo shows promise after standard treatment fails
- Promising combo therapy for head and neck cancer hits early snag